2-Chloro-5-Iodobenzoicum Acidum CAS 19094-56-5 Empagliflozin Intermedia Intende ≥99.0% (HPLC)

Description:

Nomen chemicum: 2-Chloro-5-Iodobenzoicum Acid

CAS: 19094-56-5

Dic: ≥99.0% (HPLC)

Aspectus: Crystal Alba aut pallide Yellow

Intermedia Empagliflozin (CAS: 864070-44-0) ad curationem generis diabete II

High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Manufacturer Supple, Puritas, Commercial Productio
Nomen chemicum: 2-Chloro-5-Iodobenzoicum Acid
CAS: 19094-56-5

Chemical Properties:

Nomen chemicum	2-Chloro-5-Iodobenzoic Acid
CAS Number	19094-56-5
CATTUS Number	RF-PI438
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C7H4ClIO2
M. Pondus	282.46
Solubilitas	Solutum in Methanol
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	White or Pale Yellow Crystal
Asssay / Analysis Methodo	≥99.0% (HPLC)
Liquescens punctum	161.0~163.0℃
Damnum in Siccatio	≤0.50%
Residere in Ignition	≤0.20%
Totalis immunditias	≤1.0%
Metalla gravis	≤20ppm
Residua solvens	Ethanol
Test Standard	Enterprise Standard
Consuetudinem	Medium Empagliflozin (CAS: 864070-44-0)

2-Chloro-5-Iodobenzoic Acidum (CAS 19094-56-5)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;A luce et humore protege.

commoda:

FAQ:

Applicatio:

2-Chloro-5-Iodobenzoic Acidum (CAS: 19094-56-5) adhiberi potest ut medium pharmaceuticum in synthesi Empagliflozin (CAS: 864070-44-0).Empagliflozin (commercium nomen Jardiance) est inhibitor sodii Glucosi co-portatoris-2 (SGLT-2), et facit sacchari in sanguine a renibus excernendi et in urina removendi.Die 1 Augusti 2014, Cibus et Drug Administration (FDA) publice approbavit medicamentum pro curatione diabete type II, ut sanguinem Glucosum adultorum emendare et regere posset.Empagliflozin tertia est SLLT-2 medicamenta inhibentia FDA probata.Alia duo medicamenta inhibitoria SGLT-2, Canagliflozin et Dapagliflozin, quae ad pharmaceutica Johnson, AstraZeneca et Bristol-Myers Squibb respective, a FDA mense Novembri 2013 et Ianuario 2014 approbata sunt.